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 Anion Recognition 
Anion recognition is a phenomenon in which a molecule selectively binds to a negatively 
charged substrate using reversible, typically non-covalent or coordinative interactions (Figure 
1).1, 2 
 
Figure 1 Schematic representation of anion recognition. 
In the aforementioned process, the molecule used to bind the anion is referred to as the receptor 
or host. The receptor molecule has strategically arranged convergent binding sites that can 
interact with the anion to form a product, which is also called a complex or a supramolecule. 
Selective anion binding can be achieved if the electronic character and geometry of the binding 
pocket of the receptor complements those of the anion. Moreover, the binding sites in a receptor 
should be spatially organized in such a way that they attract the anion without generating 
unfavorable repulsive interactions.  
The anion binding event often begins with a conformational reorganization of the receptor to 
arrange the binding sites in the optimal way to bind the anion and simultaneously to minimize 
steric hindrance. When a receptor does not need to undergo a large change in its conformation 
for binding to occur, the receptor is preorganized.2 It is important to mention that a 
conformational reorganization of the receptor is associated with an entropic and possibly 
enthalpic penalty that reduce complex stability. Preorganized receptors thus typically form more 
stable complexes than non-preorganized ones.  
Also, solvation, i.e. the interaction of solvent molecules with the receptor and the anion, plays a 
substantial role in anion recognition.3 
 
Figure 2 Schematic representation of anion binding that includes solvent reorganization.  
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As shown in Figure 2, the receptor and the substrate are surrounded by solvent molecules in 
solution. During complexation, some of these interactions with the solvent molecules are broken 
to allow the receptor to interact with the anion. The Gibbs free energy gained by complex 
formation should overcompensate the energy required for desolvation. Moreover, the release of 
solvent molecules from a receptor and an anion during complex formation into the bulk 
increases the entropy, while the conformational restriction of the binding partners causes a loss 
of entropy. Thus, the final balance of all the enthalpic and entropic contributions determine the 
affinity of a receptor to an anion in a particular solvent.3 
 Significance of Anion Recognition 
In the past few decades, anion coordination chemistry has experienced an exponential growth 
that is partly related to the significance of anion recognition in various fields as shown 
schematically in Figure 3.4, 5, 6, 7 
For instance, the presence or concentration of toxic or environmentally deleterious anions can be 
monitored through anion sensing. Anion sensing by means of molecular receptors can be 
achieved if the recognition of an anion by a receptor produces a response, be it optical (change 
of color or fluorescence), electrochemical, or associated with a sol-gel transition. Anion 
receptors can also be employed to remove toxic anions (TcO4
-, CN-, AsO4
3-) from the 
environment via selective extraction. In metallurgy, metallate anions or ion pairs can be 
extracted by anion recognition.8 
In biology, anions are transported across membranes by specific proteins in order to maintain the 
optimum concentration within the cell and the cellular compartments. Defects in these proteins 
affect their transporting ability, thus causing a number of diseases such as cystic fibrosis,9 
certain types of Bartter syndrome,10 11 Pendred syndrome,12 congenital chloride diarrhea,13 and 
other genetic diseases. These disorders could be treated by replacing the malfunctioning proteins 
with synthetic anion receptors that can transport anions across phospholipid membranes.  
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Figure 3 Possible application of anion receptors. 
Molecular recognition is also of central importance in bio- and organocatalysis. That anion 
receptors can also contribute as catalysts to the field of organocatalysis has nevertheless been 
recognized only recently.5, 14, 15 
 Strategy to Design Receptors for Anion Recognition 
The key factors that should be considered during the design of a selective host are the properties 
of the anion that should be bound. Specifically, the binding pocket of the receptor should ideally 
be complementary to the structure of the target anion. In addition, it should contain appropriate 
acidic groups that can engage in non-covalent attractive interactions with the anion. A strategy 
to realize such a pocket involves arranging appropriate anion binding sites in a convergent 
arrangement around a cavity.  The examples of typical anion binding motifs are depicted in 
Figure 4.16, 7, 17 
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Figure 4 Examples of typical anion binding motifs. 
One strategy to recognize anions makes use of their Lewis bases nature, which enables selective 
and strong coordination to suitable Lewis acidic metal ions.18, 19, 20 The coordination bonds thus 
formed have a high degree of directionality and often a high thermodynamic stability. 
Quaternary ammonium ions can be used in receptors to mediate anion affinity by electrostatic 
interaction.21, 22, 23 
Hydrogen bond donors are functional groups in which one or more hydrogen atoms are 
connected to an electronegative atom (oxygen, sulfur, or nitrogen). The electronegative atom 
reduces the electron density on the hydrogen atom directly attached to it. The resultant electron 
deficient hydrogen atom interacts with the anion by an attractive force called hydrogen bond.24 It 
is noteworthy that the strength of the resulting hydrogen bond reflects the sum of different 
interactions, namely, dipole-dipole interaction, London dispersion, and charge-transfer 
interactions. The strength of hydrogen bonds, which ranges in a wide range (2-180 kJ/mol),25 
and their good directionality render this type of interaction very useful for anion recognition. 
Chapter 1- Intoduction  
7 
 
 
Figure 5 Examples of novel anion binding motifs. 
Recent investigations have shown that polarized C-H groups can also engage in hydrogen 
bonding interactions with anions (Figure 5). The C5-H bond of 1,4-disubstituted 1,2,3-triazole 
rings, in particular, represents a versetile anion binding motif.26, 27, 28, 29 This bond was found to 
be a stronger hydrogen bond donor than aliphatic C-H bonds due to its large dipole moment, 
which is almost collinear with the C-H bond,  and has the positive end oriented in the direction 
of the hydrogen atom. The triazole C-H is, however, a weaker donor than conventional hydrogen 
bond donors. Another advantage of 1,2,3-triazoles is their easy accessibility by means of 
copper(I)-catalyzed azide-alkyne cycloaddition.30 
A strategy to recognize anions that has only been recently found wider application is by means 
of halogen bonding (XB) interactions.31 A halogen bond is an attractive non-covalent interaction 
between an electrophilic region in a covalently bonded halogen atom and a Lewis base 
(anion).32, 33, 34, 35 The halogen bond ability of halogens increases as they become larger (F- << 
Cl- < Br- < I-). These interactions have long been exploited as a tool in crystal engineering for 
their powerful ability to direct supramolecular self-assembly36 whereas molecular recognition in 
solution using halogen bonding has been overlooked for some time.  
Halogen bonding interactions R-X···A- have some characteristic features. The interatomic 
X···A- distance is, for example, shorter than the sum of the van-der-Waals radii of the two 
interacting atoms and the optimal angle of the interactions is close to 180°.37, 38  The interaction 
strength of halogen bonding lies in the range 10-200 kJ/mol,39 which is similar to that of 
hydrogen bonding interactions. However, XB interactions have an increased preference for 
linearity and are more hydrophobic in nature than HB interactions. Figure 5 shows commonly 
employed halogen bond donors for the development of anion receptors.  
Incorporation of a positive charge into HB or XB donor motifs (termed charged 
hydrogen/halogen bond donors) increases the degree of polarization of hydrogen/halogen bonds, 
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thus strengthening the corresponding interactions. The charged nature of the resulting receptors 
also cause electrostatic interaction to contribute to binding. Charged receptors are also typically 
better soluble in polar solvents so that anion binding studies become possible under more 
competitive conditions. Examples of charged hydrogen bond and halogen bond donors are also 
included in Figure 4 and Figure 5.  
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 State of Art 
 Triazole C-H as anion binding motif 
The 1,2,3-triazole unit has many properties that make it well suited as a building block in anion 
receptors. Firstly, the heterocycle is readily prepared using Cu(I)-catalyzed 1,3-dipolar 
cycloadditions (Figure 6).30, 40, 41 
 
Figure 6 Cu(I)-Catalyzed 1,3-dipolar cycloaddition reaction affording a 1,4-disubstituted 1,2,3-triazole 
unit. The red arrow indicates the dipole moment µ of the 1,2,3-triazole unit in Debye (D).  
Secondly, the electronic structure of the triazole ring is highly relevant for anion binding.29, 27 
The three electronegative and sp2 hybridized nitrogen atoms resided together on one side of the 
ring while the C-H bond resides on the opposite side. This arrangement creates a large dipole 
moment with its axis almost collinear with the C-H bond and the positive end located at the C-H 
group. The electronegativity of C5-carbon atom is further augmented by its sp2 hybridization and 
the presence of the clustered nitrogen atoms. As a consequence, the proton on C5 is capable of 
engaging in hydrogen bonding interactions with anions. In this context, the geometry of the 
1,2,3-triazole offers favorable features for constructing macrocyclic receptors. It is planar and 
has only minor steric bulk. The two substituents in 1-and 4- position of five-membered ring are 
arranged at a slightly larger angle than two meta- oriented substituents in a six-membered 
aromatic ring thus decreasing the steric hindrance with nearby groups.  
The first example of a triazole C-H containing receptor is macrocycle 1 (Chart 1), which was 
prepared from the respective 1,3-diethynyl benzene and 1,3-diazido benzene precursors by 
means of copper-catalyzed azide-alkyne cycloaddition.42 Compound 1 coordinates to chloride in 
dichloromethane with high affinity (Ka = 1.3 x 10
5 M-1).  Size selectivity was observed because 
1 forms less stable complexes with smaller fluoride and larger bromide and iodide anions. This 
receptor was developed in the Flood group in which various structural analogs of 1 were also 
prepared and investigated with respect to their anion coordination properties.27 
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Chart 1 
Almost simultaneously, the anion binding properties of oligomer 2 (Chart 1), the acyclic analog 
of 1, comprising alternating triazolyl and 1,3-disubstituted phenylene subunits were reported. 
Like macrocycle 1, 2 binds to inorganic anions via C-H····anion interactions.43 Anion binding 
studies demonstrated that 2 adopts a helical conformation in the presence of suitable anions with 
all the triazole C-H bonds directed towards the guest anion within the central cavity. Oligomer 2 
binds to both chloride and bromide in acetone-d6 at 25 °C with respective binding constants of 
Ka = 1.7 x 10
4 M-1 and Ka = 1.2 x 10
4 M-1. However, the binding affinity of 2 is significantly 
lower for iodide due to the larger radius and an improper fit of this anion within the helix cavity.  
The increase of the length of oligomer 2 and introduction of chiral side-chains on every second 
phenylene subunits afforded 3 (Chart 2).44 This compound adopts a two-turn helical 
conformation in water/acetonitrile further stabilized by π-stacking of the overlapping strands and 
solvophobic effects. The presence of chloride and bromide causes inversion of helicity, with the 
latter anion having the largest effect. This helix inversion in response to an achiral stimulus is 
unique. The authors claim that it is induced by halide binding to the chiral side chains of 3, 
which alters the transfer of helicity of the substituents to the aromatic backbone, thus producing 
an inversion from left- to right-handed helicity.44 
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Chart 2 
While a large number of anion receptors containing either amide45, 46, 47 or triazole26, 27 subunits 
are known, a limited number of receptors exist that can bind to anions through a combination of 
amide N-H····A- and triazole C-H····A-  interactions. Li et al have synthesized the prototype 
receptor 4a, containing three distinct types of hydrogen bond donors, namely, O-H, N-H and C-
H groups to assess their different contributions to the interactions with various anionic guests. 
This receptor exhibits the highest affinity for fluoride in acetone-d6 (Chart 3).
48 
Subsequently, the same group reported the oligomer 4b containing three triazolecarboxamide 
subunits as an anion receptor (Chart 3).49 Anion binding of 4b was investigated in CD2Cl2 by 
using 1H-NMR titrations. The presence of anions induces folding of 4b to afford a conformation 
with all the triazole C-H bonds directed towards the anion bound within the central cavity. 
Among all the tested anions, sulfate forms the most stable complex (Ka = 1.3 x 10
3 M-1).  
 
Chart 3 
The amidetriazole was further employed as an anion-binding motif to prepare receptors 5a-b for 
oxyanion recognition (Chart 4).50 The linear receptor 5a forms a complex with sulfate in which 
two anions binds to one receptor molecule. The affinity for the first anion is significantly higher 
than for the second. The tripodal receptor 5b also displays high affinity for sulfate. X-ray crystal 
structure analysis revealed that in this case a 1:1 complex is formed, in which one sulfate anion 
hydrogen bonds to the N-H, C-H, and O-H groups of 5b.  
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Chart 4 
In terms of structure, triazole subunits have other key features that extends beyond anion 
coordination chemistry into the field of peptidomimetics.51, 52 1,2,3-Triazole rings share both 
electronic and topological characteristics with amide groups (Figure 7), in that both groups are 
of similar size and possess similar H-bonding donor and acceptor capabilities.53, 54, 55 In addition, 
the incorporation of a 1,2,3-triazole ring into a molecule provides access to both “trans” and 
“cis” peptide mimics according to the substitution pattern on the triazole. Specifically, 1,4-
disubstituted 1,2,3-triazoles mimic the trans whereas 1,5-substituted 1,2,3-triazoles the cis 
conformation of the amide bond.56, 57 
 
Figure 7 Similarities of trans-amides and cis-amides with 1, 4-disubstituted (a) and 1,5-disubstituted (b) 
1,2,3-triazoles. 
Advantage of 1,2,3-triazoles is their proteolytic and metabolic stability with respect to amide 
bonds.56, 58 Thus, the use of 1,2,3-triazole as bioisosteres for amide bonds has been recognized 
for some time.  Davis et al. reported the triazolopeptide 6b, an analog of the anticancer 
compound (6a) (Chart 5).59 In their work, the authors studied the utility of different moieties as 
amide bond surrogates. Evaluation of the compounds in vitro revealed that only the 1,4-
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disubstituted 1,2,3-triazole moiety could be incorporated in the cyclopeptide without reduction 
of its cytotoxicity.  
 
Chart 5 
The trans-amide bond of compound 7a (compound 7a is a Sunflower trypsin inhibitor 1 (SFTI-
1) and act as protease inhibitor) was replaced by a 1,2,3-triazole unit between the prolyl and the 
alanyl residue.60 In this work, the authors reported the use of both 1,4- and 1,5- disubstituted 
1,2,3-triazole as amide bond surrogates. Only compound 7b, which mimics the trans 
conformation of parent macrocycle 7a, exhibits biological activity.60 
 Triazole C-I as anion binding motif 
1,4-Disubstituted 5-iodo-1,2,3-triazole (iodotriazole) moieties have recently gained increasing 
attention as XB donors in anion receptors.61 Similar to the prototriazole analog, iodotriazole 
rings are readily prepared by using a copper(I)-catalyzed cycloaddition between an azide and a 
terminal alkyne in the presence of an iodinating agent (triiodide) in one pot (Figure 8).62,63 In 
analogy to the C-H bond polarization within 1,2,3-triazoles, a significant C-X bond polarization 
can be expected in 5-iodo-1,2,3-triazoles due to the presence of three nitrogen ring atoms.64 
Other structural properties such as planarity and ring size of prototriazole are essentially 
preserved in iodotriazoles.  
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Figure 8 One pot synthesis of 1,4-disubstituted 5-iodo-1,2,3-triazoles by using Cu(I)-catalyzed 1,3-
dipolar cycloaddition in the presence of triiodide. The red arrow indicates the dipole moment (µ) of the 
5-iodo-1,2,3-triazole unit. 
A number of computational and experimental studies indicated that an anisotropic distribution of 
electron density around the iodine atom in the 1,4-disubstituted 5-iodo-1,2,3- triazole subunit 
generates a localized region of depleted electron density along the C-I axis, termed as σ hole.65 
Electrostatic interactions between the σ hole and electron donating species such as anions are 
termed halogen bonding (XB) (Figure 9).35 XB interactions are considered to be of comparable 
strength to HB interactions but have a stricter linear geometry and different steric requirements. 
These properties render the 1,4-disubstituted 5-iodo-1,2,3-triazole subunit an attractive anion 
binding motif for incorporation into the binding pockets of anion receptors. 
 
 
Figure 9 Schematic representation of the electrostatic interaction between the σ hole of the iodine atom 
in a 1,4-disubstituted 5-iodo-1,2,3-triazole ring and an anion. 
Several anion receptors containing iodotriazole subunits have been reported in the past few 
years. Schubert et al. prepared bidentate receptors 8a-b in which a carbazole scaffold is 
symmetrically functionalized with two iodotriazole units (Chart 6).66 X-ray crystallographic and 
NMR spectroscopic experiments indicated that intramolecular OH····N hydrogen bond 
interactions in 8b preorganize the two triazole into a syn-syn arrangement, which is optimal for 
anion recognition. Isothermal titration calorimetry in THF indicated that bromide and chloride 
form 2:1 complexes in which one anion binds to two receptor molecules with the accumulated 
binding constants Ka equal to 2.1 x 10
8 M-2 and 2.2 x 108 M-2, respectively. The complexation is 
enthalpically and entropically favored. Receptor 8a, lacking the OH groups, forms less stable 
complexes with the same anions due to the greater entropic penalty that has to be paid during 
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complex formation with respect to 8b. This outcome confirms that the preorganization of 8b has 
a favorable effect on anion affinity. 
In the bimetallic bis-triazole pyrimidine derived receptors 9a-b (Chart 6), the chelation of the 
two Re(I) centers preorganizes the triazole groups as well as increases the degree of polarization 
of the C-I and C-H bonds.67 The binding affinity and selectivity of the iodine containing receptor 
9b for a range of halides and oxoanions are quite different from the ones of the structural analog 
9a, containing two prototriazole moieties. Halides, hydrogen carbonate, and acetate have higher 
affinities for 9b in 50 vol% CDCl3/CD3OD, whereas 9a is a slightly superior ligand for H2PO4
-, 
ClO4
-, SO4
2-, and NO3
-. Moreover, 9a shows little discrimination among the monovalent anions 
(92 ≤ Ka ≤ 548 M-1), whereas a clear selectivity for I- (Ka > 104 M-1) was observed in the case of 
XB receptor 9b. 
 
Chart 6 
Subsequently, Beer’s group introduced the acyclic receptors 10a-b, comprising four iodotriazole 
subunits (Chart 6).68 The neutral tetradentate XB foldamer 10a exhibits higher affinity for iodide 
(Ka = 2.7 x 10
3 M-1) over the smaller halides, carboxylate, and dihydrogen phosphate (DHP) 
anions in 50 vol% CDCl3/acetone-d6. The foldamer 10b with a chiral (S)-binaphthol subunit is 
able to distinguish between the enantiomers of chiral amino acids. The highest enentioselectivity 
was observed for tryptophan (KD/KL = 1.69), followed by leucine (KD/KL = 1.52) and alanine 
(KD/KL = 0.79), which correlates with the steric bulk of the amino acid side chain. 
The same group recently introduced a neutral all-XB [2]rotaxane 11, which is equipped with 
three convergent iodotriazole donors (Chart 7).69 This host displays a significantly improved 
selectivity for halide anions over AcO- in CHCl3 compared to an acyclic model system, 
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comprising the isolated bis-iodotriazole Re(I) complex. The halide selectivity trend (Cl- > Br- > 
I-) suggests a size complementarity between the [2]rotaxane’s binding cavity and the Cl- anion. 
Importantly, no interactions between the metal-free analog of rotaxane 11 and halide anions 
were observed, which highlights the pivotal role of the Re(I) center in preorganizing and 
polarizing the ring bis-iodotriazole XB donor groups.  
 
Chart 7 
Beer et al. prepared the tetrapodal receptor 12b (Chart 8) by installing four iodotriazole 
containing arms onto a picket-fence-style Zn(II) metalloporphyrin scaffold.70 Anions are bound 
by 12b via XB interactions to the four C-I groups and by coordinative interactions with the 
Lewis acidic Zn(II) center. The anion recognition properties of 12b and of its structurally 
analogous HB receptor 12a (Chart 8) were investigated by means of UV-visible titration 
experiments in CHCl3, acetone, and acetonitrile. Both receptors prefer the complexation of 
oxoanions over halide anions, with the trend in halide binding affinities correlating with the 
charge density of the anion (Cl- > Br- > I-). The XB receptor 12b has a higher affinity for halides 
than the HB receptor in all three solvents, whereas the same trend was not observed for the 
oxoanions. Moreover, the anion affinities of both receptors were shown to strongly depend on 
the solvent (acetone > acetonitrile > chloroform).  
The 3,5-bis-(iodotriazole)-pyridinium subunit was incorporated into [2]catenane 13b (Chart 8) 
by using a chloride-templated ring-closing metathesis ‘clipping’ reaction.71 This receptor binds 
to halides with a markedly higher affinity than the all-HB catenane 13a (Chart 8). Compound 
13b has a strong preference for I- and Br- over the smaller Cl- anion in 45:45:10 
CDCl3/CD3OD/D2O. Interestingly, 13b binds to oxoanions, AcO
-, and H2PO4
- too weakly for 
binding affinity to be quantified. Single crystal X-ray structural analysis confirms the 
incorporation of the halides into the cavity of 13b.  
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Chart 8 
Clipping of a ring around a bis-iodotriazole pyridinium subunit with two appended 
permethylated β-cyclodextrin stoppers afforded the water soluble dicationic [2]rotaxane 14b 
(Chart 8).72 1H-NMR titration experiments revealed that halide and sulfate affinities of the 
prototriazole analog 14a (Chart 8) in D2O are modest whereas the [2]rotaxane 14b containing 
the XB donors binds strongly to these anions. Iodide affinity of the XB rotaxane 14b 
(Ka  = 2.2  x  10
3 M-1) is particularly improved over that of 14a (Ka = 20 M
-1). The complexation 
of iodide by 14a is enthalpically disfavored and entropically driven as a consequence of the 
release of D2O molecules from the host and guest upon anion binding. Conversely, the binding 
of I- by the bis-iodotriazole rotaxane 14b is entropically unfavorable and driven by a favorable 
enthalpic contribution which suggests the formation of strong C-I····I- bonds.  
Most anion receptors containing 1,4-disubstituted 5-iodo-1,2,3-trizole (iodotriazole) building 
blocks reported so far are non-cyclic, containing typically up to four iodotriazole subunits as 
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binding sites or feature interlocked molecular components such as the receptors developed in the 
Beer group.61. Macrocyclic receptors with a converging arrangement of several halogen-bond 
donors are, however, rare. The only example is a family of cyclophanes developed by Beer et al. 
featuring two bromoimidazolium units in the ring that bind halides in 90 vol% CH3OH/H2O by 
combining electrostatic interactions with XB. In addition, there is a single example of a cyclic 
receptor, namely 15a (Chart 9) comprising a crown ether embedded 5-iodo-1,2,3-triazole ring. 
This ion-pair receptor simultaneously binds to both the anion and the cation of sodium iodide 
(Chart 9).64 Affinity in 75 vol% CD2Cl2/CD3CN is low due to the poor solubility of sodium 
iodide in organic solvent and the non-ideal fit of the sodium with the cation cavity. However, 
15a exhibits overall higher affinity for NaI (Ka = 541 M
-1) than the prototriazole containing 
macrocycle 15b (Ka = 174 M
-1). 
 
Chart 9 
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 Scope of the doctoral work 
The main objectives of this thesis were to develop novel cyclic pseudopeptides containing 
multiple binding sites for anion recognition and investigate their anion affinity. 
 
Chart 10 
Cyclic pseudohexapeptide 16 (Chart 10) is structurally based on an anion-binding cyclopeptide 
19 and an anion-binding cyclic pseudopeptide 20 previously reported in the Kubik group.73, 74 
The main structural difference is the presence of the 1,4-disubstituted 1,2,3 triazole subunits that 
also induce a larger cavity diameter with respect to the previous receptors. Cyclic pseudopeptide 
16 was expected to feature a converging arrangement of amide N-H groups and triazole C-H 
groups, which should thus both be able to contribute to anion binding. My work involved the 
synthesis of 16 and the assessment of the influence of the triazole units on anion affinity. 
The results obtained for 16 indicated that the larger analog, cyclic pseudooctapeptide 17 (Chart 
10), could also possess interesting binding properties because of its higher flexibility with 
respect to 16, its larger cavity, and higher number of triazole C-H and amide N-H groups. 
Pseudopeptide 17 was therefore included into the work. 
The third pseudopeptide developed during this thesis is the cyclic pseudohexapeptide 18 (Chart 
10) that is structurally related to 16 but contains iodine atoms in the 5-position of the triazole 
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subunits.  This compound should therefore have a smaller cavity diameter than 16 and should be 
able to exhibit a converging arrangement of amide N-H and triazole C-I groups which should 
thus both be able to engage in interactions with anions. My work involved the synthesis of 18 
and the assessment of the influence of the iodine atoms on anion affinity. 
 
 Chapter 2 
 
 
Anion binding to a cyclic pseudopeptide containing 
1,4-disubstituted 1,2,3-triazole moieties 
 
 
 
[D. Mungalpara, H. Kelm, A. Valkonen, K. Rissanen, S. Keller, S. Kubik "Oxoanion binding to 
a cyclic pseudopeptide containing 1,4-disubstituted 1,2,3-triazole moieties" Org. Biomol. 
Chem. 2017, 15, 102-113]. Copyright by the Royal Society of Chemistry (RSC). Reproduced with 
permission. 
 
My work that led to this publication comprised the synthetic work including the characterization 
of the prepared compounds and their crystallization. In addition, I performed all binding studies 
by using ITC and NMR spectroscopy. Dr. Herald Kelm helped in solving the crystal structure of 
the free cyclic pseudopeptide. Prof. Dr. Kari Rissanen and Dr. Arto Valkonen solved the crystal 
structure of the receptor-DHP complex. Prof. Dr. Sandro Keller helped in the interpretation of 
the ITC results. Prof. Dr. Stefan Kubik acted as scientific supervisor. 
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 Scope of the work 
Cyclic hexapeptide 19 (Chart 11), comprising alternating 6-aminopicolinic acid and L-proline 
subunits has been shown to efficiently bind to inorganic anions even in competitive aqueous 
solvent mixture such as 80 vol% water/methanol.73 The X-ray crystal structure analysis of the 
trihydrate of 19 shows that the peptide adopts a C3 symmetric conformation in the crystal. All 
the protons of the N-H groups are arranged in a convergent fashion.  This can be explained by 
the presence of the pyridine units that destabilize arrangements of the neighboring carbonyl 
oxygen atoms pointing into the direction of the free electron pairs on the ring nitrogen atoms 
(Chart 11). Another characteristic structural feature of 19 is that the tertiary amides adopt the cis 
conformation causing the planes of the aromatic units to lie approximately parallel to the C3 axis 
of the macrocycle.  
           
Chart 11 
In 80 vol% water/methanol, 19 has highest affinity for iodide and sulfate. Complexation of these 
anions involves sandwiching them between two cyclopeptide rings, producing (19)2·(anion)1 
complexes (Chart 11). The stability of these complexes in aqueous media is attributed to the 
shielding of the bound anion from the surrounding solvent and hydrophobic interactions 
between the cyclopeptide rings. 1H-NMR spectroscopy and isothermal titration calorimetry 
showed that the overall stability constants of the iodide and sulfate complexes of 19 amount to 
ca. 105 M-2 in 80 vol% water/methanol.73  Interestingly, protonated oxoanions such as hydrogen 
phosphate or dihydrogen phosphate anions bind significantly less strongly to 19 because of 
repulsive interactions between the protons on these anions and the  hydrogen bond donors inside 
the cavity between two cyclopeptide rings.  
 
Crystal structure of (19)2·I
- 
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In subsequent work, the unusual binding properties of 19 were transferred to a structural analog, 
namely the cyclic pseudopeptide 20 (Chart 12) that features similar conformations.74 In 20, the 
pyridine units also induce converging arrangement of the N-H groups. The tertiary amide groups 
in 19 are replaced by 1,5-disubstituted 1,2,3-triazole rings that are known to act as surrogates for 
cis-peptide bonds.75 Pseudopeptide 20 was shown to also interact with anions in highly 
competitive media although its propensity to form sandwich type complexes is lower than that 
of 19.74 
 
Chart 12 
In this work, the family of anion-binding cyclopeptides and pseudopeptides should be extended 
to compound 16, containing 1,4-disubstituted triazole rings (Chart 12). This pseudopeptide 
should again feature converging N-H groups due to the orienting effects of the pyridine nitrogen 
atoms. However, the conformation of 16 should significantly differ from the ones of 19 or 20 
because of the structural relationship of 1,4-disubstituted triazoles to trans-amides.51 The 
advantage of 16 in terms of anion affinity should be a higher number of hydrogen bond donors 
with respect to 19 and 20 because the triazole C5-H groups should be able to participate in anion 
binding. To demonstrate the effect of the triazole units in 16 on the conformation, the solid-state 
structures of compounds 19, 20, and the calculated structure of 16 are compared in Figure 10.  
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Figure 10 Comparison of crystal structures of cyclopeptide 19 (a) and cyclic pseudohexapeptide 20 (b) 
with the calculated structure of cyclic pseudohexapeptide 16 (c). In the cases of 19 and 20, solvent 
molecules are omitted for the clarity. The structure of 16 was calculated by using Spartan 04 for 
Macintosh (Wavefunction, Inc.) with the MMFF force field and without considering solvent molecules. 
All three structures are approximately C3-symmetric and share the converging arrangement of 
the N-H groups. The pseudopeptides 20 and 16 differ in the orientation of the triazole C-H 
groups. Whereas the triazole C-H groups point away from the anion binding site in 20 they are 
arranged close to the converging N-H groups in 16, thus potentially allowing them to contribute 
to anion binding. In addition, the three macrocycles differ in the diameter of the ring, which is 
larger for 16 due to the 1,4-disubstituted triazole units than for 19 or 20. Moreover, the aromatic 
rings in 16 are slightly more tilted than in 19 and 20. In order to experimentally elucidate the 
effect of the 1,4-disubstituted 1,2,3-triazole units in 16 on anion binding, the objective of this 
thesis was to prepare this pseudopeptide, assign its conformation in solution and evaluate its 
binding properties. 
 Results  
 Synthesis 
According to a retrosynthetic analysis, 16 can be assembled either from the monomer 21a by 
using standard peptide synthesis, or from 21b by using repeated Cu(I)-catalyzed click chemistry 
(Chart 13). Since carboxylic acids with a stereogenic center in α-position that carries an 
additional triazole unit are extremely prone to racemization,76, 77 the second approach was used 
to synthesize 16. 
 
Chart 13 
(a) (b) (c) 
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Firstly, the known linear monomer 2177 was converted into the azide 22 and the unprotected 
alkyne 23, both of which were then coupled under the conditions of CuAAC to afford the linear 
dimer 24 (Figure 11). This dimer was further elongated to the linear trimer 25 by deprotecting 
the alkyne moiety in 24 and performing another azide-alkyne cycloaddition using 22 as the azide 
component.  
 
Figure 11 Synthesis of the linear trimer 25a. 
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Figure 12 Synthesis of the cyclic pseudopeptide 16. 
The linear timer 25 was made ready for cyclization by, first, cleaving the TMS group and then 
substituting the mesylate group with an azide group to afford 25a. Initially, small-scale 
cyclizations were performed under different reaction conditions to find suitable conditions that 
afford 16. The courses of these test reactions were followed by HPLC. The conditions employed 
are summarized in Table 1. All small-scale cyclization reactions were performed under dilute 
condition by dissolving 25a in tert-butanol/water, 1:1 (v/v) at a concentration of 852 µM. In 
reactions CR1 and CR2, 50 mol% and 100 mol% of Cu(MeCN)4PF6, TBTA, and sodium 
ascorbate were used, respectively. In reaction CR3, the reaction mixture was initially treated 
with 10 mol% of these reagents and additional 5 mol% of reagents (Cu(MeCN)4PF6 and TBTA) 
were added every 24 h till the complete disappearance of the peak associated with the starting 
material in the HPLC chromatogram.   
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Table 1 Amount of reagents used for the cyclization of 25a in tert-butanol/water, 1:1 (v/v) at 25 °C. 
Entry 25a 
mg (µmol) 
Solvent 
mixture (mL) 
Cu(MeCN)4PF6
(mol%) 
TBTA 
(mol%) 
Sodium 
ascorbate (mol%) 
CR1 11.0 (17) 20 50 50 50 
CR2 11.0 (17) 20 100 100 100 
CR3 11.0 (17) 20 10+(2x5)a 10+(2x5)a 5 
CR4b 120.0 (186) 200 10+(5x5)a 10+(5x5)a 5 
a5 mol% of Cu(MeCN)4PF6, TBTA, and sodium ascorbate were added to the reaction mixture CR3 for 3 
days after an initial reaction time of 24 h; bCR4 reaction mixture was heated at 35 °C after 96 h. 
The rates of cyclization in reactions CR1 and CR2 were very slow and large amounts of starting 
material were present even after 96 h. The conditions employed in CR3 proved to be more 
beneficial for the cyclization. Figure 13 shows the chromatograms obtained after 24 h, 48 h, and 
72 h under these conditions.  
 
Figure 13 HPLC chromatogram of the cyclization reaction CR3 after 24 h (a), 48 h (b), and 72 h (c). 
The peaks at 11 min and 16 min correspond to the product 16 and the starting material 25a, 
respectively. The repeated addition of the reagents resulted in the gradual increase in the 
intensity of the product peak with the concomitant decrease of the educt peak. After 72 h, almost 
all of the starting material was consumed. 
The cyclization was subsequently performed in four different solvents, namely, 
dichloromethane, 1,4-dioxane, 1,4-dioxane/water, 1:1 (v/v), and tert-butanol/water, 1:1 (v/v) 
using condition CR3.  Among the tested solvents, the cyclization proceeded best in tert-
butanol/water, 1:1 (v/v).  
Starting material 25a 
Cyclic Product 16 
t (min) 
(a) 
(b) 
(c) 
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Figure 14 HPLC chromatogram of cyclization reaction CR4 after 24 h (a) 48 h (b) 96 h (c) 120 h (d) 144 
h (e) and 168 h (f). After 96 h the reaction was heated to 35 °C.  
A large-scale cyclization (CR4) was performed under the optimized conditions by using 120 mg 
of 25a. According to the HPLC analysis, conversion was very slow and a large amount of 
starting material was present even after 96 h. Therefore, this reaction mixture was heated to 
35°C and addition of 5 mol% of the reagents (Cu(MeCN)4PF6 and TBTA) was continued. Under 
these conditions, almost all of the starting material was consumed after additional 72 h 
(Figure 14).  
Thus, all the later cyclizations were performed using the optimized conditions at 35 °C. 
Purification of 16 was achieved by performing washing, extraction, and crystallization steps 
without requiring chromatography. The analytically pure product was isolated with a yield of ca. 
30%. Further information about the synthesis of 16 and the purification is available in the 
respective publication (Chapter 2.5).78 
 Structural Assignment and Anion Binding Properties 
X-ray crystallography showed that 16 adopts a conformation in the solid state with the N-H 
groups and the triazoles C-H groups converging towards the cavity center. NOESY NMR 
spectroscopy indicated that this conformation is also preferred in solution (DMSO-d6). Binding 
studies were performed in D2O/DMSO-d6 or water/DMSO mixtures containing between 0.03 
vol% and 5 vol% of water using 1H-NMR spectroscopy and microcalorimetry, respectively.  The 
25a 
16 
(a) 
(b) 
(c) 
(d) 
(e) 
(f) 
t (min) t (min) 
16 
25a 
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results of these investigations are described in detail in the corresponding publication (Chapter 
2.5).78 
Anion binding investigations were also performed in 5 vol% DMSO-d6/acetone-d6. Initially, 
1H-
NMR spectra were recorded of solutions containing 16 in concentration varying between 
0.1 mM to 1.0 mM to see whether the pseudopeptide aggregates in this solvent within this 
concentration range. Figure 15 shows that the signals of 16 do not shift or exhibit broadening 
when increasing the concentration, suggesting that aggregation does not occur. Therefore, 1H-
NMR spectroscopic experiments were performed to evaluate qualitatively and quantitatively the 
anion binding properties of 16 in this solvent.  
 
Figure 15 1H-NMR spectra of solutions containing 0.1 mM (a),  0.25 mM (b), 0.50 mM (c), 0.75 mM 
(d), and 1.00 mM (e) of 16 in 5 vol% DMSO-d6/acetone-d6. The signals assigned are indicated in the 
structure on the right hand side by using the same color code.  
To this end, the 1H-NMR spectra of solutions of cyclic pseudopeptide 16 (1 mM) in 5 vol% 
DMSO-d6/acetone-d6 that additionally contained 5 equiv of the tetrabutylammonium salts of 
various anions were recorded at 25 °C and compared with the spectrum of the free 
pseudopeptide in the same solvent. The corresponding NMR spectra are depicted in Figure 16. 
These spectra show that the anions mainly cause downfield shifts of three signals, namely, those 
of the N-H, TriC-H protons as well as the signals of the protons on the stereogenic centers of 16, 
C*-H. The signal belonging to the peripheral methyl groups (C*-CH3) of 16 is also affected but 
to a significantly smaller extent. These qualitative binding experiments indicated that all the 
ppm 
(a) 
(c) 
(d) 
(e) 
(b) 
N-H 
TriC-H 
ArC-H 
C*-H 
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investigated anions interact with 16 in 5 vol% DMSO-d6/acetone-d6. Assuming that binding 
strength is proportional to the extent of the induced signal shifts, H2PO4
- (DHP) is most strongly 
bound. In the case of the DHP and sulfate anions, the NH signal is not visible in the spectrum 
presumably because these anions promote H/D exchange. In addition, the signals of 16 broaden 
in the presence of sulfate anions.  
 
Figure 16 1H-NMR spectrum of 16 (1 mM) in 5 vol% DMSO-d6/acetone-d6 in the absence (a) and the 
presence of 5 equiv. of TBA iodide (b), nitrate (c) hydrogen sulfate (d) bromide (e), chloride (f), 
dihydrogenphosphate (g), and sulfate (h).  
  
N-H 
TriC-H C*-H 
(d) 
(c) 
(b) 
(a) 
(e) 
ppm 
ArC-H 
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Subsequently, Job’s method of continuous variation was used to determine the stoichiometry of 
the chloride complex of 16. The respective 1H-NMR spectra are depicted in Figure 17. 
 
Figure 17 1H-NMR spectra of 16 and TBA chloride in 5 vol% DMSO-d6/acetone-d6 at mol fractions X 
of the partner ranging between 0.0 and 0.9 mol% of TBA chloride and a total concentration of 1 mM. 
The Job plots constructed by following the chemical shifts of the N-H, TriC-H, and C*-H 
signals are displayed in Figure 18. These Job plots indicate that 16 preferentially forms a 1:1 
complex with the chloride anion.  
 
Figure 18 Job plots for the chloride complex of 16 in 5 vol% DMSO-d6/acetone-d6. The three curves 
were constructed by following the courses of the N-H (stars), TriC-H (circles), and C*-H (squares) 
signals in the NMR spectra depicted in Figure 17. 
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Subsequently, NMR titrations were performed by following the effects of the gradual addition of 
the TBA salts of chloride, bromide, hydrogen sulfate (HS) and DHP to a solution of 16 in 5 
vol% DMSO-d6/acetone-d6. Under these conditions, the signals of the free receptor and its DHP 
complex are simultaneously visible in the spectra of a solutions containing less than one 
equivalent of the salt, showing that complex formation is slow on the NMR time-scale.  Thus, 
the association constant of the DHP complex of 16 could not be determined. The broadening of 
the receptor signals in the presence of TBA sulfate also precluded quantification of the stability 
of the sulfate complex.   Binding of the other anions is fast on the NMR time-scale, allowing 
binding isotherms to be constructed from the gradual shifts of the receptor signals observed 
when increasing the amount of the salt. As an example, the 1H-NMR spectra obtained in the 
titration with TBA chloride are depicted in Figure 19. 
 
Figure 19 1H-NMR spectra of 16 (0.5 mM) in 5 vol% DMSO-d6/acetone-d6 containing increasing 
equivalents of TBA chloride, specified to the left of each spectrum. 
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The isotherms obtained from the shifts of the N-H, TriC-H and C*-H were globally fitted to 
different binding models by using HypNMR2008. The fitted isotherms are shown in graphs in 
Figure 20.  
 
Figure 20 Binding isotherms obtained in the NMR titration of 16 with TBA chloride by following the 
shifts of the TriC-H (a), N-H (b), and C*-H (c) signals. Fitting of isotherms was performed by using 
HypNMR2008.  
Fitting only gave satisfactory results if formation of higher complexes was considered in which 
two anions bind to the receptor. Only in the case of the nitrate complex were the results 
consistent with a 1:1 complex. Table 2 summarizes the obtained binding constants. In all cases, 
the first binding step is significantly stronger than the second one, with chloride anions forming 
the most stable 1:1 complex. Affinity decreases in the order of chloride > bromide > hydrogen 
sulfate > nitrate. The effect of the addition of TBA iodide to a solution of 16 in 5 vol% DMSO-
d6/acetone-d6 proved to be too weak to allow quantification of binding strength.  
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Table 2 Stability constants of the chloride, bromide, hydrogen sulfate (HS), and nitrate complexes of 16 
in 5 vol% DMSO-d6/acetone-d6 determined by NMR titrations.  
anion log K11a log K12b 
chloride 4.0 1.5 
bromide 3.4 2.4 
HS 3.0 1.4 
nitrate 2.4 - 
 aEquilibrium constant describing the formation of the 1:1 complex; bEquilibrium constant describing the 
formation of the 16·(anion)2 complex from the 16·anion complex; errors are estimated to amount to ca. 
±10%. 
 Discussion 
X-ray crystallography and NOESY NMR spectroscopy confirm the C3 symmetric conformation 
of 16 as well as the expected convergent arrangement of three amide N-H and triazole C-H 
protons. Thus, the conformation observed in the solid state and solution is in good agreement 
with the conformation of the calculated one. The amide N-H and triazole C-H protons point 
towards the narrow opening of the receptor and create an electropositive binding site where an 
anion can coordinate to all six hydrogen donors. 
In the less competitive solvent (5 vol% DMSO-d6/acetone-d6), pseudohexapeptide 16 interacts 
with a variety of anions as indicated by pronounced shifts of receptor signals upon addition of 
different TBA salts. The signals most affected are the ones of the N-H, triazole C-H, and the C*-
H protons, which all move downfield upon anion binding. As all of these protons are arranged at 
the narrow opening of the receptor one can assume that anion binding take place there. The 
extents of the signal shifts differ significantly among the different anions. In the case of halides, 
chloride induces the strongest shift and iodide the weakest. For the oxoanions, the anion effect is 
weakest for nitrate and strongest for sulfate and dihydrogenphosphate (DHP). Quantitative 
binding studies showed that complexation of DHP is slow on NMR time-scale and sulfate 
causes broadening of receptor signals. While this precluded quantification of binding strengths it 
shows qualitatively that very stable complexes are formed, consistent with the qualitative 
binding study. All other anions form complexes whose complexation/decomplexation rates are 
fast on the NMR time-scale. Among the anions investigated chloride forms the most stable 1:1 
complex, which is consistent with the fact that chloride is a strongly coordinating anion. 
However, formation of higher complexes is observed, indicating that once the first anion is 
bound, binding sites remain empty on the receptor that allow complexation of a second anion. 
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Such 16·(anion)2 complexes are unusual as binding of the second anion has to overcome charge 
repulsion suggesting efficient stabilization. Similar types of complexes have been recently 
reported for the cyclic peptide unguisin A that can coordinate to two anions (chloride, bromide 
and bicarbonate).79 The fact that the binding constants of the second binding steps are smaller 
than the ones of the first steps shows that the second anion is less efficiently stabilized than the 
first, also explaining why the second binding step is not visible in the job plot of chloride 
complex (Table 2). That two anions can be bound by 16 is probably a consequence of the size of 
the cavity.  
In the competitive solvent (2.5 vol% D2O/DMSO-d6), only binding of the more strongly 
coordinating oxoanions sulfate, DHP, and HPP is retained. These anions form complexes 
differing in stoichiometry. Sulfate and HPP complexation involves a stepwise process 
comprising formation of a 16·anion complex followed by a (16)2·(anion) complex. Formation of 
the higher complexes indicates that 16 cannot saturate all acceptor sites of the anion so that the 
anions can recruit a second receptor molecule.  In contrast, 16 binds to two DHP anions in 
solution. This stoichiometry is different from the one detected in the solid state where a trimer of 
DHP is stabilized by two pseudopeptide rings. While close spatial arrangement of two or more 
anions in the solid-state may look unusual, the tendency of DHP anions to form such aggregates 
is well known.80 Charge repulsion upon DHP association can obviously be overcompensated by 
sufficiently strong hydrogen bonding interactions between two DHP anions.80, 81 While isolated 
DHP aggregates are only weakly stable in a polar medium such as DMSO, suitable receptors 
such as pseudopeptide 16 can cause their efficient stabilization. The formation of a 162·(DHP)3 
complex as found in the solid state seems to be entropically unfavourable in solution so that only 
a 16·(DHP)2 complex was observed under these conditions.  
 Summary 
The cyclic pseudohexapeptide 16 was successfully synthesized. X-ray crystallography showed 
that it adopts a conformation in the solid state with the N-H groups and the triazole C-H groups 
converging towards the cavity center. NOESY NMR spectroscopy indicated that this 
conformation is also preferred in solution (DMSO-d6).  
Pseudopeptide 16 is only soluble in organic solvents such as 5 vol% DMSO-d6/acetone-d6 and 
DMSO containing up to 5 vol% of water. In 5 vol% DMSO-d6/acetone-d6, 16 binds to chloride, 
bromide, nitrate, hydrogen sulfate, sulfate, and dihydrogen phosphate anions. Quantitative 
binding studies demonstrated that chloride, bromide, and hydrogen sulfate are bound in the 
forms of (16)·(anion)2 complexes in this solvent mixture. The exact structure of these complexes 
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could not be determined. The binding of sulfate and DHP in 5 vol% DMSO-d6/acetone-d6 is 
slow on the NMR time-scale. 
In 2.5 vol% D2O/DMSO-d6, 16 only binds to strongly coordinating oxoanions. The respective 
complexes differ in their stoichiometries. In the case of DHP, two anions are bound by 16 in 
solution whereas sulfate and HPP complexation involves a stepwise process, comprising 
formation of a 1:1 complex followed by binding of second pseudopeptide ring. The stability 
constant associated with the second binding step is smaller in comparison to the first one in the 
case of sulfate complexation, while the two binding constants are of similar magnitude in the 
case of HPP binding. 
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 Chapter 3 
 
 
Efficient stabilization of phosphate aggregates by a 
cyclic pseudopeptide containing 1,4-disubstituted 
1,2,3-triazole moieties 
 
 
 
[D. Mungalpara, A. Valkonen, K. Rissanen, S. Kubik "Efficient stabilisation of a 
dihydrogenphosphate tetramer and a dihydrogenpyrophosphate dimer by a cyclic pseudopeptide 
containing 1,4-disubstituted 1,2,3-triazole moieties" Chem. Sci. 2017, 8, 6003-6013]. Copyright 
by the Royal Society of Chemistry (RSC). Reproduced with permission. 
 
 
My tasks of the work described in this publication involved the design, synthesis, purification, 
and characterization of the cyclic pseudooctapeptide. I also crystallized this compound in its free 
form and its phosphate complexes, and performed the binding studies by using ESI-MS, ITC, 
and NMR spectroscopy. Prof. Dr. Kari Rissanen and Dr. Arto Valkonen solved the crystal 
structures. Prof. Dr. Stefan Kubik acted as scientific supervisor.  
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 Scope of the Work 
The structural characterization of cyclic pseudopeptide 16 showed that it features the expected 
converging arrangement of the amide N-H and triazole C-H groups. High anion affinity was 
therefore observed in organic solvents in which 16 is soluble. The binding studies also revealed, 
however, that the interactions of 16 with the studied anions are often complex.  The 
complexation typically involved the formation of higher complexes in which either more than 
one pseudopeptide binds to one anion or more than one anion binds to one pseudopeptide. This 
result was attributed to the fact that high conformational rigidity and the large cavity size of 16 
do not allow the saturation of all hydrogen bond acceptor sites of oxoanions by a single 
pseudopeptide ring. A strategy to simplify complex formation would involve using a more 
flexible derivative of 16 that is able to fold around an anion, thus forming a 1:1 complex.  
Molecular modeling indicated that a larger analog of 16, cyclic pseudooctapeptide 17, could be 
able to adopt folded conformations to wrap around an anion (Chart 14). Another advantage of 17 
is the higher number of anion binding sites with respect to 16 that could also improve the anion 
affinity. 
 
Chart 14 
Figure 21 shows that 17 is able to adopt a conformation with all eight hydrogen bond donors of 
the amide N-H and triazole C-H groups arranged around the ring. Should an anion included into 
this cavity be able to interact with these binding sites, stabilization could be specifically high 
and should not involve formation of complexes with a higher stoichiometry. Based on this 
assumption, pseudopeptide 17 should be synthesized and its binding properties investigated.  
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Figure 21 Calculated structure of cyclic pseudopeptide 17: side view (a) top view (b). The calculations 
were performed by using the MMFF force-field implemented in Spartan 10. A Monte-Carlo 
conformational search was performed without restricting the number of considered conformations. After 
initiating the calculation, 39366 conformations were expected to be calculated. The search aborted after 
122 conformations, however, after which no further improvement could be achieved. 
  
(a) (b) 
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 Results  
 Synthesis 
Synthesis of 17 was based on the strategy developed for 16. The synthetic route is depicted in 
Figure 22 and Figure 23. The synthesis started with dimer 24, which was also an intermediate in 
the synthesis of 16. Compound 24 was converted into the azide 26 and the alkyne 27, both of 
which were then coupled under CuAAC conditions to afford the linear tetramer 28 (Figure 22). 
The linear tetramer 28 was made ready for cyclization by, first, cleaving the TMS group and 
then substituting the mesylate group with an azide group to afford 28a by using the established 
reaction conditions (Figure 22). 
 
Figure 22 Synthesis of linear tetramer 28a. 
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Compound 28a was cyclized by using conditions also employed for the synthesis of 16 (Figure 
23). 
 
 
Figure 23 Synthesis of the cyclic pseudooctapeptide 17. 
For the cyclization, the linear tetramer 28a was initially treated with 10 mol% of 
Cu(MeCN)4PF6, TBTA, and sodium ascorbate in tert-butanol/water, 1:1 (v/v) and the 
progression of the cyclization was followed by HPLC. 
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Figure 24 HPLC chromatograms of the cyclization reaction in tert-butanol/water, 1:1 (v/v) after 24 h (a), 
48 h (b), and 72 h (c). Extra 5 mol% of Cu(MeCN)4PF6 and TBTA were added after every 24 h. 
By assuming that the product 17 and the starting material 28b have same extinction coefficients, 
Figure 24 shows that conversion only amounted to ca. 30 % after 24 h with a large amount of 
the starting material still being present. Therefore, additional 5 mol% of Cu(MeCN)4PF6 and 
TBTA were added every day which caused the starting material to be nearly consumed after 
72 h. The shape of the product peak at the end of the reaction indicated the presence of an 
impurity with almost the same retention time. Both products could be separated by column 
chromatography on silica gel using DCM/acetone 2:1 (v/v) as the eluent during work-up. 
MALDI-TOF mass spectrometric analysis showed that the two products have the same mass, 
indicating that they are isomers.  
Starting material 28b 
Compound 17 
(a) 
(b) 
(c) 
t (min) 
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Figure 25 1H-NMR spectra recorded in DMSO-d6 of the product mixture (a), and of the major (b) and 
the minor (c) component of the isolated mixture. The signals assigned are indicated in the structure on the 
right hand side by using the same color code. The signals denoted with the blue and the black dots 
represent the ones of the minor and the major product, respectively. 
The major fraction of the purified product has a simple 1H-NMR spectrum (Figure 25c), 
indicating that it is the desired C4 symmetric product. The minor fraction has a complex 
1H-NMR spectrum (Figure 25b) which shows that this compound has a reduced 
symmetry. Preliminary X-ray crystallographic results indicated that this minor product 
contains one S-configured stereogenic center while all the others have the correct R-
configuration (Figure 25). Formation of this product thus results from epimerization of a 
stereogenic center during one synthetic step. Since no evidence for the formation of 
diastereomers could be found in the 1H-NMR spectra of the linear precursors of 17, 
epimerization likely only occurs during or after cyclization, which was performed at an 
elevated temperature.76 Further information about the synthesis and purification of 17 is 
available in the manuscript (Chapter 3.5). 
ppm 
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 Structural Assignment and Anion Binding Properties 
The results of the structural assignment of pseudopeptide 17 and of the anion binding 
studies are described in the manuscript (Chapter 3.5). Only the most important results 
will therefore be summarized here.   
1H-NMR spectroscopy indicates that 17 adopts an averaged C4 symmetrical conformation 
in DMSO-d6. The NOESY NMR spectrum in the same solvent shows that the amide N-
H, triazole C-H, and the C*-H are oriented in one direction.  
Binding studies were restricted to three anions, namely, sulfate, DHP, and DHPP as guests in 2.5 
vol% water/DMSO to allow comparison with the properties of the smaller analog 16, whose 
interactions with anions were studied under analogous conditions. Binding studies were 
performed by using ESI mass spectrometry, 1H-NMR spectroscopy, and microcalorimetry.  
The ESI mass spectra of solutions of 17 (0.5 mM) in DCM containing the TBA salts of sulfate 
(1 equiv), DHPP (1 equiv), or DHP (2 equiv) show signals at m/z ratios that could be assigned to 
the respective anion complexes of the pseudopeptide. In the case of sulfate, a signal for the 1:1 
complex was observed, whereas the signals visible in the spectra recorded in the presence of 
DHP and DHPP were consistent with (17∙DHP2)2 and (17∙DHPP)2, respectively (Table 3). These 
spectra thus indicate that only sulfate seems to form the expected 1:1 complex with 17 while the 
phosphate-derived anions prefer the formation of higher complexes. 
Table 3 Main signals (m/z) present in the ESI mass spectra of solutions of 17 (0.5 mM) in DCM 
containing different anions as their respective TBA salts. 
anion Equiv m/z Complex 
sulfate 1.0 859.49 [17-H]
- 
 1198.54 [(17∙SO42-)∙TBA]- 
DHP 2.0 783.89 [(17DHP2)2∙TBA]
3- 
 957.38 [17∙DHP]- 
 1297.00 [(17∙DHP2)2∙TBA2]2- 
DHPP 1.0 771.89 [(17∙DHPP)2∙TBA]
3- 
 1279.02 [(17∙DHPP)2∙TBA2]2- 
 
X-ray crystallographic analysis of crystals of the DHP and DHPP complexes of 17 confirmed 
these stoichiometries, showing that the DHPP complex comprises a dimer of this anion 
sandwiched between two pseudopeptide rings while two pseudopeptides bind to a tetramer of 
the anion in the case of the DHP complex (Figure 26). When crystals of 17 were grown from 
acetone in the presence of TBA HPP, the sandwich-type complex between 17 and the DHPP 
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dimer was also found, indicating that complex formation is associated with anion protonation 
(Figure 26). Moreover, the thus obtained crystals are centrosymmetric and contain both 
enantiomers of 17. The receptor therefore seems to racemize in the presence of (basic) HPP 
anions.  
 
Figure 26 Crystal structures of (17∙DHP2)2 (a) (17∙DHPP)2 (b) ((S)17∙DHPP)2 (c) ((R)17∙DHPP)2 (d) 
complexes.  
1H-NMR spectroscopy showed that complex formation also takes place in solution. Figure 27 
shows the 1H-NMR spectra of solutions of 17 in 2.5 vol% D2O/DMSO-d6 containing the TBA 
salts of DHP (2 equiv), HPP (0.5 equiv), DHPP (0.5 equiv), and sulfate (0.5 equiv) in 
comparison to the 1H-NMR spectrum of the free pseudopeptide. 
In the presence of sulfate, signal shifts are observed of the triazole C-H and C*-H signals of 17 
that are qualitatively similar albeit smaller than the shifts observed in the 1H-NMR spectrum 
when TBA sulfate was added to pseudopeptide 16 in the same solvent. Since only a single set of 
signals is visible in the presence of substoichiometric amount of sulfate, complex formation is 
fast on the NMR time-scale. In contrast, two sets of signals appear in the spectra once a  
(a) (b) 
(c) (d) 
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phosphate derived anion is present, accounting for binding equilibria that are slow on the NMR 
time-scale. Moreover, the signal set belonging to the complex contains twice the number of 
signals in comparison to the spectrum of free receptor, which shows that the averaged C4 
symmetry of 17 is reduced to C2 upon phosphate binding.  
 
 
Figure 27 1H-NMR spectra of 17 (0.5 mM) in 2.5 vol% D2O/DMSO-d6 in the absence (a) and the 
presence of TBA sulfate (0.5 equiv) (b), DHP (2 equiv) (c), HPP (0.5 equiv) (d), DHPP (0.5 equiv) (e). 
The signals denoted with the green and the red dots represent the ones of 17 in the free and complexed 
states, respectively.  
ITC confirmed that TBA sulfate forms 1:1 complex with 17 in 2.5 vol% water/DMSO. 
The stability constant of the corresponding complex is one order of magnitude lower than 
that of the 1:1 sulfate complex of 16 (Table 4). Moreover, ring enlargement causes 
sulfate binding to go from exothermic for 16 to endothermic for 17. 
  
(a) 
(c) 
(d) 
(e) 
(b) 
ppm 
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Table 4 Stability constants and thermodynamic parameters of the TBA sulfate complexes of 16 and 17 in 
2.5 vol% water/DMSO.  
Receptor log K11a 
 
log K21b ΔH°11c 
kJ/mol 
TΔS°11c 
kJ/mol 
16 4.2 < 3.2 -9.8 12.2 
17 3.2 - 6.1 23.6 
aEquilibrium constant describing the formation of the 1:1 complex. bEquilibrium constant describing the 
formation of the 162·SO42- complex from the 1:1 complex. cEnthalpies and entropies associated with the 
formation of the 1:1 complexes. 
 
The complexation of DHP and DHPP by 17 is strongly exothermic. Deriving binding 
constants for the individual binding steps associated with the formation of 172·(DHP)4 
and 172·(DHPP)2 complexes from the binding isotherms proved to be not possible 
because too many species are involved in the equilibria. The sharp transition of the 
binding isotherm indicated, however, that complex formation proceeds in a cooperative 
fashion in the case of DHPP. On the other hand, the isotherm of the DHP complexation 
has a complex shape, thus, a part of isotherm was considered during the quantification of 
the stability constant.  The binding isotherms were therefore fitted by using a simplified 
binding model that neglects the oligomerization equilibrium of the DHP and DHPP 
anions and assuming that the DHPP dimer or the DHP tetramer bind as a single entity to 
two molecules of 17 in a stepwise fashion. The thus obtained binding constants are 
summarized in Table 5. 
Table 5 Stability constants and thermodynamic parameters of the TBA DHP and DHPP complexes of 17 
in 2.5 vol% water/DMSO.  
Anion log K11a log K21b log β 
ΔH°c 
kJ/mol 
TΔS°c 
kJ/mol 
DHPP 6.3 6.4 12.7 -53.3 19.1 
DHPd 5.6 4.0 9.6 -42.8 12.0 
aEquilibrium constants describing the formation of the 17·(DHP)4/17·(DHPP)2 complexes. 
bEquilibrium constants describing the formation of the 172·(DHP)4/172·(DHPP)2 complexes from 
the respective 17·(DHP)4/17·(DHPP)2 complexes. cCumulative enthalpies and entropies 
associated with the formation of the 172·(DHP)4/172·(DHPP)2 complexes. 
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 Discussion 
The design of 17 was based on the assumption that this pseudopeptide can fold around an anion 
so that formation of higher complexes that were observed for 16 could be avoided. According to 
1H-NMR and NOESY NMR spectroscopy, 17 adopts an averaged C4 symmetric conformation in 
solution with all H-bond donors oriented into the same direction. The converging arrangement 
of neighboring N-H, TriC-H and C*-H protons is also visible in the calculated structure of 17 
(Figure 21). This calculated structure is, however, C2 symmetric and therefore less symmetric 
than the averaged conformation detected in solution because of the folding of the macrocycle. It 
is therefore reasonable to assume that 17 is flexible in solution, which causes averaging over 
several conformations, possibly including the ones that are most stable according to the 
calculations, so that a simple 1H-NMR spectrum results. The low solubility of 17 in organic 
solvents precluded measuring 1H-NMR spectra at lower than room temperature to confirm this 
assumption. 
The presence of sulfate anions in 2.5 vol% D2O/DMSO-d6 causes typical downfield 
shifts of H-bond donor protons of 17 in the 1H-NMR spectrum, indicating that the anion 
is hydrogen bonded to these protons. Microcalorimetry indicated formation of a 1:1 
complex of moderate stability. Complexation is associated with a small favourable 
entropic and an unfavourable enthalpic contribution. The unfavorable enthalpy is 
attributed to the weak hydrogen bonding interactions between sulfate and the receptor 
due to the improper fit of the anion into the large cavity whereas the favourable entropy 
could be due to the release of solvent molecules from the receptor and the anion upon 
binding.  
The complexation of phosphate derived anions by 17 is more interesting. Pseudopeptide 
17 is able to stabilize a tetramer of DHP and a dimer of DHPP by sandwiching these 
anionic aggregates between two pseudopeptide rings. Pseudopeptide 17 therefore shares 
with the smaller analog 16 the ability to stabilize the aggregates of phosphate-derived 
anions. The respective complexes of 17 are, however, structurally better defined as the 
same stoichiometries were found in the solid state, in solution, and even in the gas phase. 
The cyclic arrangement of four DHP anions in the DHP complex of 17 has so far not 
been observed in other system. A DHPP dimer, has been observed in the respective 
complex of a pyrrole-derived receptor.82  
While the conformation of the individual pseudopeptide rings are almost C4 symmetric in 
these complexes, the overall symmetry of the complexes is C2 because the two 
pseudopetides adopts an offset arrangement.  This arrangement seems to be retained in 
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solution and the dynamic exchange is slow on the NMR time-scale as demonstrated by 
the splitting of the signals of 17 in the 1H-NMR spectrum into two signal sets upon 
complex formation.  
No quantitative information about complex stability could be derived by NMR 
spectroscopy and the stability of the DHPP and DHP complexes was therefore evaluated 
in 2.5 vol% water/DMSO by using microcalorimetry. 
These investigations indicate that the binding of these anions to 17 seems to proceed in a 
highly cooperative fashion, involving a single step in the binding isotherms. These 
isotherms were therefore fitted to a simplified binding model, which neglected the 
oligomerization equilibria of the anions. With a log K11 of 6.3 and a log K21 of 6.4, the 
stepwise binding constants of the DHPP complex are nearly equal in size, leading to a 
log β of 12.7 for the overall stability of the complex. This log β only qualitatively reflects 
the actual stability of the DHPP complex of 17 as the oligomerization equilibrium of the 
anion is neglected. The fact that the second stability constant is larger than log (K11/4) is 
consistent with cooperative binding.83 The thermodynamic parameters associated with 
the overall binding constants indicate that DHPP and DHP binding is enthalpically 
(negative ΔH) as well as entropically favourable (positive TΔS). Stability of the 
(17∙DHP2)2 and (17∙DHPP)2 complexes is in fact so high that these complexes can even 
be transferred into the gas phase without decomposition as demonstrated by ESI mass 
spectrometry. The high stability of these complexes could be attributed to various 
attractive interactions between the complex components, namely, hydrogen-bonding 
between the anions, multiple hydrogen bonding interactions between the anion oligomers 
and the hydrogen bond donors of 17, and dispersive interactions between the closely 
arranged pseudopeptide rings. In combination, these stabilizing effects allow to overcome 
charge repulsion of the individual anions. 
The propensity of 17 to bind to the DHPP dimer is also reflected by the fact that the 
(17∙DHPP)2 complex even forms when TBA HPP was used instead of TBA DHPP as 
substrate. Complex formation thus causes a shift of the HPP/DHPP protonation 
equilibrium to the diprotonated form of the anion, which can then be bound. The protons 
required for this process likely derive from the water present in the solvent, which should 
cause the solution to become basic. The concomitant basicity of the solution would 
explain why the pseudopeptide seems to racemize in the presence of HPP.  
In conclusion, by enlarging the ring of 16 to afford 17, the anion binding equilibrium 
could be simplified but only for sulfate, with the corresponding complexes being not very 
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stable. A more interesting feature of pseudopeptide 17 is its ability to stabilize aggregates 
of phosphate-derived anions. The high stability of the corresponding complexes could 
allow the development of phosphate selective receptors whose selectivity derives from 
the unique ability of such anions to form higher aggregates.  
 Summary 
The cyclic pseudooctapeptide 17 containing 1,4-disubstituted 1,2,3-triazole moieties was 
synthesized. This pseudooctapeptide binds to the sulfate anion in 2.5 vol% water/DMSO 
in the form of a 1:1 complex with moderate affinity (log Ka = 3.2). Dihydrogen phosphate 
(DHP) and dihydrogen pyrophosphate (DHPP) anions are, however, strongly bound. 
Complexation of these anions involves sandwiching of a DHPP dimer or a DHP tetramer 
between two pseudopeptide rings. The structure of these complexes was determined by 
X-ray crystallography. 1H-NMR spectroscopy, mass spectrometry, and isothermal 
titration calorimetry showed that they are highly stable in solution (2.5 vol% 
water/DMSO) and in the gas phase. This stability was attributed to multiple hydrogen 
bonding between the individual anions and between the anion oligomers and the 
hydrogen bond donors of 17. In addition, dispersive interactions between the closely 
arranged pseudopeptide rings in the sandwich complexes likely also contribute to 
complex stability.  
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A neutral halogen bonding macrocyclic anion receptor 
based on a pseudocyclopeptide with three 5-iodo-1,2,3-
triazole subunits 
 
 
 
 
 
 
[D. Mungalpara, S. Stegmüller, S. Kubik "A neutral halogen bonding macrocyclic anion 
receptor based on a pseudocyclopeptide with three 5-iodo-1,2,3-triazole subunits" Chem. 
Comm. 2017, 53, 5095-5098]. Copyright by the Royal Society of Chemistry (RSC). Reproduced 
with permission. 
 
My contributions to this publication were the development of the synthesis of the described 
pseudopeptide, its purification, and characterization, and I also performed all the binding 
investigations. Ms. Simone Stegmüller helped with some of the LC-MS experiments. Prof. Dr. 
Stefan Kubik acted as scientific supervisor.  
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 Scope of the Work 
As described in Chapter 2, pseudopeptide 16 strongly binds to oxoanions such as sulfate, DHP 
or HPP, but the complexation equilibria are often complex, involving the binding of more than 
one anion to the pseudopeptide ring or more than one pseudopeptide to an anion. The second 
strategy pursued in this work to simplify anion binding involved the replacement of the protons 
in the 5-position of the triazole moieties of 16 with iodine atoms to afford 18 (Chart 15). 
 
Chart 15 
These iodine atoms should allow 18 to engage in anion binding by XB interactions.61 
They should also decrease the cavity size and therefore alter anion selectivity of 18 in 
comparison to that of 16 in favor of smaller anions.  
DFT calculations were performed based on the crystal structure of 16 to gain insight into 
the influence of the iodide atoms in 18 on cavity size and anion binding. The results of 
these calculations are compared with the solid-state structure of 16 in Figure 28. 
      
Figure 28 Calculated structures of pseudopeptide 18 (a), crystal structure of 16 (b) and calculated 
structure of the chloride complex of 18 (c). DFT calculations were performed by using the B3LYP 
functional implemented in Spartan 10 (Wavefunction, Inc.) with the 6-311G* basis set. 
Figure 28 shows that the iodine atoms in 18 significantly reduce the diameter of the 
binding site of the pseudopeptide. Moreover, the calculated structure of the chloride 
(a) (b) (c) 
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complex suggests that the distance and orientation of the iodine atoms should be well 
suited for binding of this small halide, which can make contact to the σ-holes of all three 
iodine atoms in the complex with no need for a major conformational reorganization of 
the receptor. Pseudopeptide 18 should therefore be synthesized and its anion binding 
properties evaluated.  
 Results 
 Synthesis 
Synthesis of cyclic pseudohexapeptide 18 started from the central building block 21, which was 
also used for the preparation of 16. Chain elongations and cyclization were achieved by repeated 
copper-catalyzed iodoalkyne-azide cycloaddition reactions (CuIAAC), yielding the desired 1,4-
disubstitited 5-iodo-1,2,3-triazole subunits (Figure 29 and Figure 30).  
 
Figure 29 Synthesis of linear pseudohexapeptide 30. 
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In the first step, equal amounts of 21 were converted into the azide 22 and the alkyne 23. 
Compounds 22 and 23 were coupled under appropriate conditions to yield the linear dimer 29.  
This dimer was converted into the azide 29a and coupled to 23, again using CuIAAC, to afford 
the linear trimer 30 (Figure 29). Treatment of 30 with tetrabutylammonium fluoride followed by 
iodination afforded the iodoalkyne-containing linear trimer 30b (Figure 30). 
 
Figure 30 Synthesis of the pseudocyclohexapeptide 18. 
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To test whether the iodoalkyne group is stable during the subsequent substitution reaction, the 
independently prepared model compound 31 was initially treated with NaN3 in DMF at 50 °C. 
Under these conditions, the corresponding azide 31a was cleanly obtained without affecting the 
iodalkyne moiety (Figure 31). The same reaction conditions were therefore used to convert 30b 
into the corresponding azide 30c (Figure 30).   
 
Figure 31 Conversion of the model monomer 31 into the azide 31a. 
The cyclization of the linear trimer 30c to obtain 18 was the most challenging step of this 
synthesis. Initially, small scale cyclizations were performed using the conditions collected in 
Table 6. These conditions were chosen because examples of macrocyclization reactions using 
these methods are reported in the literature.84, 64, 85  All small-scale cyclization reactions were 
performed under dilute condition using 617 µM solutions of 30c in various dry solvents. In the 
reactions CR1 and CR2, 20 mol% of CuI and of TBTA were added initially to the reaction 
mixture and 10 mol% of both reagents were added every 24 h till the complete disappearance of 
the peak associated with the starting material in the HPLC chromatogram.  In reaction CR3, a 
solution of 30c in acetonitrile was passed through a coil of copper tube using a syringe pump at 
elevated temperature (70 °C).  In this case, the copper tube should serve as a Cu(I) source.  
Table 6 Attempted cyclization reactions involving 30c by using different copper sources and solvents. 
All reactions were performed at 25 °C.  
Entry 
30c 
(µmol) 
Copper source 
Cu-catalyst 
(mol%) 
TBTA 
(mol%) 
Solvent 
CR1 37 CuI 20+(4x10)a 20+(4x10) a THF 
CR2 37 CuI 20+(4x10) a 20+(4x10) a methanol 
CR3 37 copper tube coil - - acetonitrileb 
a10 mol% of CuI and TBTA were added to the reaction mixture CR1 and CR2 after every 24 h, bThe 
reaction was stirred at 70 °C.  
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Conversion in all reactions was followed by HPLC-MS. Examples of chromatograms are shown 
in Figure 32. According to the mass spectroscopic analysis, the peaks at 17 min and 22 min in 
the chromatograms correspond to the cyclic product 18 and the linear precursor 30c, 
respectively. In this reaction mixture, a small amount of 30c was degraded into its deiodinated 
derivative (Figure 32a). Later, the deiodinated 30c disappeared in the HPLC chromatogram with 
the course of cyclization (Figure 32c). It is therefore assumed that the deiodinated side product 
could have either undergo oligomerization or did not elute because of poor solubility in the used 
eluents. Among these tested methods, only CR1 proved to afford the desired product. 
Consequently, these conditions were used for the synthesis of 18 on a larger scale. Purification 
of 18 involves several washing and extraction steps after which the cyclic pseudopeptide is 
obtained in analytically pure form. More details about the synthesis are available in the 
publication (Chapter 4.5). 
 
Figure 32 HPLC chromatograms of the cyclization reaction under condition CR1 obtained after 24 h (a) 
72 h (b), and 120 h (c). 
 Structural Assignment and Anion Binding Properties 
The results of the structural assignment of pseudopeptide 18 and of the anion binding 
studies are described in the publication (Chapter 4.5). Only the most important results 
will therefore be summarized here.   
1H-NMR spectroscopy indicates that 18 adopts an averaged C3 symmetrical conformation 
in DMSO-d6. The ROESY NMR spectrum in the same solvent indicated that the N-H and 
the C*-H are oriented into the same direction. Thus, the arrangement of the N-H and   
Starting material 30c 
Cyclic product 19 
Deiodinated 30c 
t (min) 
(c) 
(a) 
(b) 
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C*-H groups of 18 in solution is same as in the parent macrocycle 16.  No experimental 
information is available about the orientation of the C-I bonds, but the DFT calculations 
strongly indicate that the most stable conformation of 18 is one with C-I bonds arranged 
in a similar converging arrangement as the triazole C-H bonds in 16.   
Binding studies were performed in 2.5 vol% water/DMSO to allow comparison with the anion 
binding properties of 16. The complexation of anions with 18 was studied by ESI mass 
spectrometry, 1H-NMR spectroscopy, and microcalorimetry.  
In the ESI mass spectra of solutions of 18 (1 mM) in 50 vol% DMSO/ACN containing 1 equiv 
of the TBA salts of DHP, chloride, bromide, and iodide, peaks were observed whose m/z ratios 
could be correlated with the 1:1 complexes between 18 and these anions. No such peak was 
observed in the presence of TBA sulfate (Table 7).  
Table 7 Main signals (m/z) present in the ESI mass spectra of solution of 18 (1 mM) in 50 vol% 
DMSO/ACN containing 1 equiv of different anions as their TBA salts. 
Anion m/z Complex 
chloride 1058.00 [18·Cl
-]- 
bromide 1101.88 [18·Br
-]- 
iodide 1149.88 [18·I
-]- 
DHP 1119.99 [18·DHP]
- 
 
Mass spectra under analogous conditions were also recorded of solutions containing 18 together 
with either 1 equiv of each of the three TBA halides or 1 equiv of each TBA chloride, TBA 
DHP, and TBA sulfate. In the mass spectrum of the first solution, the most intense signal 
corresponds to the chloride complex, while smaller signals of the bromide and iodide complexes 
were also observed with the one of the iodide complex being the least intensive one. The other 
solution only gave rise to one signal in the mass spectrum corresponding to the 1:1 chloride 
complex of 18. 
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Qualitative NMR spectroscopic binding studies were performed by adding 5 equiv of the 
tetrabutylammonium (TBA) salts of different anions to solutions of 18 in 2.5 vol% 
H2O/DMSO-d6 and comparing the resulting NMR spectra with the one of the free 
pseudopeptide. H2O was used instead of D2O in the solvent mixture to prevent H/D 
exchange. The obtained spectra are depicted in Figure 34. 
 
Figure 33 1H-NMR spectrum of 18 (1 mM) in 2.5 vol% H2O/DMSO-d6 in the absence (a) and the 
presence of 5 equiv. of TBA nitrate (b), DHP (c), fluoride (d), sulfate (e), iodide (f), bromide (g) chloride 
(h). The signals assigned are indicated in the structure on the right hand side by using the same color 
code. 
These spectra show that only sulfate and the halides produce noticeable changes on the 
resonances of 18. All of these anions cause a slight deshielding of the C*-H protons. The N-H 
signal moves slightly downfield in the presence of sulfate, but upfield when a halide is present.  
NMR titrations were performed by following the effects of the gradual addition of the TBA salts 
of chloride, bromide, iodide, sulfate, and DHP to a solution of 18 in 2.5 vol% H2O/DMSO-d6. 
Only in the cases of chloride, bromide, iodide, and sulfate could changes in the signals shifts of 
18 upon addition of the anions be observed. Binding of these anions is fast on the NMR time-
scale, allowing binding isotherms to be constructed from the gradual shifts of the receptor 
signals observed with increasing amount of the salt. The isotherms obtained from the titrations 
with chloride, bromide, and iodide were globally fitted to 1:1 binding model by using 
HypNMR2008. Binding constants obtained from this method are summarized in Table 8. The 
stability of the chloride complex of 18 was also determined by using tetramethylammonium 
(TMA) chloride instead of TBA chloride. The resulting binding constant shows that the 
N-H C*-H 
ArC-H 
ppm 
(c) 
(a) 
(e) 
(b) 
(d) 
(f) 
(g) 
(h) 
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counterion has a negligible effect on chloride affinity. The sigmoidal binding isotherms obtained 
from the titration with TBA sulfate could not be fitted reliably to a reasonable binding model. 
Table 8 Stability constants and thermodynamic parameters of the TBA halide complexes of 18 in 2.5 
vol% H2O/DMSO-d6 or 2.5 vol% H2O/DMSO.  
anion log Kaa 
 
log Kab ΔH°c 
kJ/mol 
TΔS°c 
kJ/mol 
chloride 3.3 3.4 -1.4 18.2 
chlorided 3.6 n.d.e n.d.e n.d.e 
bromide 2.9 n.d.e n.d.e n.d.e 
iodide 2.2 n.d. n.d.e n.d.e 
sulfate -f    
aDetermined by NMR titration in 2.5 vol% H2O/DMSO-d6; bdetermined by ITC in 2.5 vol% H2O/DMSO; 
centhalpies and entropies; errors are estimated to amount to ca. ±10%; dTMA chloride; enot determined; 
fthe binding isotherm could not fit to a reasonable binding model. 
 
Among all the tested anions, chloride is most strongly bound in 2.5 vol% H2O/DMSO-d6 
followed by bromide and iodide. This stability trend therefore mirrors the signal intensities 
observed in the mass spectrum of 18 measured in the presence of the three halides. Anion 
affinity of 18 was also evaluated using isothermal titration calorimetry (ITC). The results of this 
investigation are also summarized in Table 8. The binding constant obtained for the chloride 
complex of 18 is in good agreement with the one of the NMR titration. Chloride binding in 2.5 
vol% H2O/DMSO is mainly due to entropy with a small favourable enthalpic contribution. The 
enthalpic contribution to bromide and iodide binding proved to be too small under these 
conditions to allow quantification of binding strength. 
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 Discussion 
The results of 1H-, 13C-, and ROESY NMR spectra are consistent with the averaged C3 
symmetrical structure of 18 in solution. Unfortunately, the spectra do not allow 
assignment of the orientation of the triazole rings. Because of the structural relationship 
between 16 and 18, combined with the information obtained by ROESY NMR 
spectroscopy and the results of the DFT calculations, it is assumed that the calculated 
structure shown in Figure 28 reflects the averaged conformation of 18 in solution. 
Binding studies in 2.5 vol% H2O/DMSO-d6 indicated that among the studied anions only 
sulfate and halides interact with 18. No interaction was observed with DHP in solution 
although this anion is strongly bound by 16. ESI MS suggests that DHP weakly binds to 
18. Sulfate affinity of 18 could not be quantified by NMR titration. This titration 
indicates that the binding mode between 18 and sulfate is complex. It also suggests that 
sulfate is presumably bound weaker by 18 than by 16.  
On the other hand, halides are bound by 18 in the form of 1:1 complexes, while 16 does 
not bind to these anions under the same conditions. The presence of the halides causes a 
slight deshielding of the C*-H protons and a shielding of the N-H protons.  It should be 
pointed out that deshielding of the C*-H protons in the presence of anions is generally 
attributed to through-space effects of the bound anions arranged close to the respective 
protons in the complex. The upfield shift of the N-H signal in the presence of halides is, 
however, atypical for anion binding. Since the calculations indicate that the N-H protons 
and iodine atoms in 18 are likely too far apart to contribute to anion binding to the same 
extent, the shielding of the N-H protons upon halide binding can be attributed to receptor 
reorganization and/or the complexation induced release of solvent (DMSO or water) 
molecules solvating the N-H groups in the absence of anions. That the N-H signal moves 
downfield in the presence of sulfate anions could indicate that the binding modes of the 
halide and the sulfate complexes are different.  
According to microcalorimetry, the halide binding is only slightly exothermic, supporting 
the assumption that the receptor has to be desolavated prior to anion binding, which is 
enthlapically costly. Complex stability therefore becomes mainly due to entropy.  
The log Ka of 3.3 observed for the chloride complex of 18 is sizeable, also considering 
that binding does not involve substantial contributions beyond XB and that it proceeds in 
a relatively competitive medium. Affinities of this order of magnitude have mostly been 
observed under similar conditions for positively charged XB receptors containing, for 
example, triazolium subunits, while neutral receptors typically exhibit lower affinity.61 
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The high chloride affinity of 18 could be attributed the rigid well preorganized 
macrocyclic structure of the pseudopeptide that also restricts anion binding to a relatively 
narrow range of anions. Thus, the iodine atoms in 18 lead to major changes in the anion 
binding properties with respect to 16 as they cause the cavity to become smaller and they 
mediate XB interactions. As a consequence, 18 exhibits affinity for halide and no or only 
a very weak affinity for oxoanions. 
 Summary 
The cyclic pseudohexapeptide 18 containing 1,4-disubstituted 5-iodo 1,2,3-triazole moieties was 
synthesized. ROESY NMR spectroscopy indicates that 18 adopts a conformation in DMSO-d6 
that is related to the one of the parent macrocycle 16.  
1H-NMR spectroscopy, mass spectrometry, and isothermal titration calorimetry demonstrate that 
18 binds to chloride, bromide, and iodide in 2.5 vol% water/DMSO,  leading to the formation of 
1:1 complexes. With a log Ka of 3.3 the chloride coplex is the most stable one and complex 
stability decreases by one order of magnitute when going to the larger halide. Oxoanions are 
significantly less strongly bound by 18 than by the parent pseudopeptide 16. No complexation of 
DHP could be detected while interactions of 18 with sulfate  cannot be excluded. A defined 
stoichiometry or stability of the sulfate complex could, however, not be determined.  
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5 Conclusion and Outlook 
During the experimental work of this thesis three novel cyclic pseudopeptides 16, 17 1nd 18 
were successfully synthesized and their anion binding properties evaluated. These compounds 
complement the series of anion-binding cyclopeptide and cyclopseudopeptide derivatives 
developed in the Kubik group by derivatives containing 1,4-disubstituted 1,2,3-triazole units 
along the ring. These subunits not only act as surrogates for trans-amide groups, they also add 
converging 1,2,3-triazole C-H or 5-iodo-1,2,3-triazole C-I groups to the receptors that, together 
with the amide N-H groups, could participate in anion binding by HB or XB interactions, 
respectively. 
 
Chart 16 
Structural studies show that all three pseudopeptides can adopt conformations with the triazole 
C-H or C-I groups pointing into the cavity center to allow them to contribute to binding. Anion 
binding of 16 could only be studied in organic media because of solubility reasons. In 5 vol% 
DMSO-d6/acetone-d6, 16 binds to chloride, bromide, nitrate, hydrogen sulfate, sulfate, and 
dihydrogen phosphate anions. Quantitative binding studies demonstrated that chloride, bromide, 
1st Generation  
Receptor: 
Cyclopeptide 19 
2nd Generation  
Receptor: 
Pseudocyclopeptide 20 
 
3
rd
 Generation Receptors: 
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and hydrogen sulfate are bound in the forms of (16)·(anion)2 complexes in this solvent mixture. 
The exact structure of these complexes could not be determined. The binding of sulfate and 
DHP in 5 vol% DMSO-d6/acetone-d6 is slow on the NMR time scale. In 2.5 vol% D2O/DMSO-
d6, 16 only binds strongly coordinating oxoanions. The respective complexes differ in their 
stoichiometries. In the case of DHP, two anions are bound by 16 in solution, whereas sulfate and 
HPP complexation involves a stepwise process comprising formation of a 1:1 complex followed 
by binding of second pseudopeptide ring. Receptor 16 thus has a propensity to form higher 
complexes with sulfate and DHP presumably because it is unable to fully saturate the acceptor 
sites on these anions for structural reasons.  
Pseudopeptide 17 was expected to form 1:1 complexes. This complex stoichiometry was 
indeed observed for sulfate binding. However, the respective complex is not very stable 
maybe because the arrangement of hydrogen bond donors of 17 along the ring is not 
optimal for sulfate complexation. Phosphate-derived anions are bound in the form of 
sandwich-type complexes in which a dimer of DHPP or a tetramer of DHP is arranged 
between two pseudopeptide rings. These higher complexes are stabilized by multiple HB 
interactions, potentially combined with dispersive interaction between the 
pseudopeptides. As a consequence, the complexes persist in solution and can even be 
transferred without decomposition into the gas phase although they are made up of up to 
six components. Fitting of the binding isotherms obtained by microcalorimetric titration 
to a simplified model demonstrated high stability.  Interestingly, the sandwich-type 
binding mode observed for the DHPP and DHP complexes of 17 is somewhat 
reminiscent of sandwich complexes of cyclopeptide 19.  
Pseudohexappetide 18 allows anion binding by halogen bonding. In addition, introduction of 
iodine atoms also affects the cavity size of the pseudopeptide, thus mediating anion selectivity. 
Interaction of 18 with oxyanions is relatively weak but binding to halides, in particular to 
chloride, which were not bound in the same solvent by 16, is strong when considering that only 
XB interactions are responsible.   
While the unusual phosphate affinity of 17 and the halide affinity of 18 are particularly 
interesting, the presence of the 1,4-disubstituted 1,2,3-triazol groups in these receptors typically 
reduce their solubility in polar protic solvents. Therefore, future work should focus on 
improving water solubility without disturbing the anion binding properties to allow these 
pseudopeptides to be used under conditions more relevant for application.  In this context, either 
converting the triazole subunits into triazolium subunits or replacing the methyl groups on the 
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stereogenic centers by the more polar side chains could be an interesting options. Examples of 
potential future receptors are shown in Chart 17. 
 
Chart 17 
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